Journal
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
Volume 41, Issue 2, Pages 335-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.ecl.2012.04.014
Keywords
Insulin-like growth factor; Cancer risk stratification; Growth hormone; Signal transduction
Categories
Funding
- BMS
- Roche
- ImClone
- GSK
- Pfizer
- Merck
- MedImmune
- United States National Institutes of Health [CA136393]
- Mayo Clinic SPORE in Ovarian Cancer
- Mayo Clinic Breast SPORE [CA116201, CA090628 K12]
Ask authors/readers for more resources
Insulin-like growth factor (IGF) plays an important role in tissue growth and development. Several studies have demonstrated the association between circulating levels of IGF-1 and -2 and cancer risk, and the IGF system has been implicated in the oncogenesis of essentially all solid and hematologic malignancies. The optimal strategy for targeting IGF signaling in patients with cancer is not clear. The modest benefits reported thus far underscore the need for a better understanding of IGF signaling, which would enable clinicians to identify the subset of patients with the greatest likelihood of attaining benefit from this targeted approach.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available